Assessment of Serum Chromogranin-A as Prognostic Factor in High-Risk Prostate Cancer

• DOI: 10.2310/jim.0b013e3181f5d610
• Publication Date: 2016-05-11T13:10:57Z
• Authors: Leonardo O. Reis; Larissa F.M. Vieira; Emerson L. Zani; Fernandes Denardi; Laurione C. de Ol...; Ubirajara Ferreira
• Keywords: Chromogranin A; Clinical Significance

Purpose The presence of neuroendocrine differentiation may play a key role in androgen-independent tumor progression. prognostic significance plasma chromogranin-A (CgA) was assessed series consecutive patients with high-risk prostate cancer (PCa). Patients and Methods Twenty-three presenting PCa 8 healthy individuals, as control group, had their blood samples collected to evaluate CgA, free total specific antigen, testosterone pilot study. correlations serum CgA levels PSA, testosterone, Gleason score, number foci hypercaptation bone scan, age, outcomes were evaluated at baseline after 12 months. Results significantly higher (mean, 8.7; range, 1.9-73) than 3.45; 0.6-5.6), P = 0.02. Analyzing only the group through correlation ranks, it observed that has low, insignificant PSA ( 0.07) metastatic extension 0.09). No association found between score 0.20), age 0.15), or disease progression 0.27). Conclusion increased compared group. However, there low known factors (such metastases) clinical deterioration. Although future studies are needed larger longer follow-up, presented data envisage limited factor.